JP2022506944A - ５－α－レダクターゼ阻害剤の局所製剤及びそれらの使用 - Google Patents

５－α－レダクターゼ阻害剤の局所製剤及びそれらの使用 Download PDF

Info

Publication number
JP2022506944A
JP2022506944A JP2021525096A JP2021525096A JP2022506944A JP 2022506944 A JP2022506944 A JP 2022506944A JP 2021525096 A JP2021525096 A JP 2021525096A JP 2021525096 A JP2021525096 A JP 2021525096A JP 2022506944 A JP2022506944 A JP 2022506944A
Authority
JP
Japan
Prior art keywords
dutasteride
finasteride
solution
oil
topical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021525096A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022506944A5 (enExample
Inventor
ケー． ジンダル，ヴィナイ
グジュラティ，マヌ
アンジェリカ オバ マグソンボル－カラーン，マリー
Original Assignee
ヴァーソナ セラピューティクス，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヴァーソナ セラピューティクス，インコーポレーテッド filed Critical ヴァーソナ セラピューティクス，インコーポレーテッド
Publication of JP2022506944A publication Critical patent/JP2022506944A/ja
Publication of JP2022506944A5 publication Critical patent/JP2022506944A5/ja
Priority to JP2024198983A priority Critical patent/JP2025032123A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/69—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing fluorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A61Q7/02—Preparations for inhibiting or slowing hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Birds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
JP2021525096A 2018-11-08 2019-11-07 ５－α－レダクターゼ阻害剤の局所製剤及びそれらの使用 Pending JP2022506944A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024198983A JP2025032123A (ja) 2018-11-08 2024-11-14 ５－α－レダクターゼ阻害剤の局所製剤及びそれらの使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862757483P 2018-11-08 2018-11-08
US62/757,483 2018-11-08
US201962889318P 2019-08-20 2019-08-20
US62/889,318 2019-08-20
PCT/US2019/060194 WO2020097284A1 (en) 2018-11-08 2019-11-07 TOPICAL FORMULATIONS OF 5-α-REDUCTASE INHIBITORS AND USES THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024198983A Division JP2025032123A (ja) 2018-11-08 2024-11-14 ５－α－レダクターゼ阻害剤の局所製剤及びそれらの使用

Publications (2)

Publication Number Publication Date
JP2022506944A true JP2022506944A (ja) 2022-01-17
JP2022506944A5 JP2022506944A5 (enExample) 2022-11-15

Family

ID=70551490

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021525096A Pending JP2022506944A (ja) 2018-11-08 2019-11-07 ５－α－レダクターゼ阻害剤の局所製剤及びそれらの使用
JP2024198983A Pending JP2025032123A (ja) 2018-11-08 2024-11-14 ５－α－レダクターゼ阻害剤の局所製剤及びそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024198983A Pending JP2025032123A (ja) 2018-11-08 2024-11-14 ５－α－レダクターゼ阻害剤の局所製剤及びそれらの使用

Country Status (4)

Country Link
US (2) US11311529B2 (enExample)
EP (1) EP3876935A4 (enExample)
JP (2) JP2022506944A (enExample)
WO (1) WO2020097284A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2882708A1 (en) 2012-08-21 2014-02-27 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
KR20240157128A (ko) 2016-03-08 2024-10-31 세이지 테라퓨틱스, 인크. 신경활성 스테로이드, 조성물, 및 그의 용도
US11311529B2 (en) * 2018-11-08 2022-04-26 Varsona Therapeutics, Inc. Topical formulations of 5-α-reductase inhibitors and uses thereof
WO2021225987A1 (en) * 2020-05-02 2021-11-11 XYON Health Inc. Topical formulations comprising dutasteride for treating dermatological disorders including male pattern baldness
US11311556B2 (en) * 2020-05-13 2022-04-26 Varsona Therapeutics, Inc. Topical dutasteride emulsions for treating endocrine therapy-induced alopecia
JP2023525160A (ja) 2020-05-13 2023-06-14 フォリクル・ファーマ・リミテッド 毛包内への生物活性剤の送達のための組成物
US11850300B2 (en) 2022-03-17 2023-12-26 Rally Guide Topical lotion composition, methods of use, and methods of preparation
WO2025163683A1 (en) * 2024-02-02 2025-08-07 Zydus Lifesciences Limited Pharmaceutical compositions of 5-alpha reductase inhibitors

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030191035A1 (en) * 2002-03-26 2003-10-09 Alberto-Culver Company Hair conditioning composition
US20060204588A1 (en) * 2005-03-10 2006-09-14 Elan Pharma International Limited Formulations of a nanoparticulate finasteride, dutasteride or tamsulosin hydrochloride, and mixtures thereof
US20090069364A1 (en) * 2003-10-10 2009-03-12 Carrara Dario Norberto R Pharmaceutical compositions of 5-alpha-reductase inhibitors and methods of use thereof
US20100048598A1 (en) * 2008-08-21 2010-02-25 Sateesh Kandavilli Topical compositions comprising 5-alpha reductase inhibitors
JP2012504135A (ja) * 2008-09-27 2012-02-16 ジャイナ ファーマシューティカルズ，インコーポレーテッド 経口適用および局所適用のための脂質系薬学的調製物、ならびにそれらの組成物、方法、および使用
JP2013543004A (ja) * 2010-11-18 2013-11-28 ホワイト マウンテン ファーマ，インコーポレイテッド 対象における慢性または解決不能な疼痛を処置するための、および／または痛覚閾値を高めるための方法、およびこれに用いる医薬組成物
JP2014500275A (ja) * 2010-12-06 2014-01-09 フォリカ，インコーポレイテッド 禿頭症を治療するため、および毛髪の成長を促進するための方法
US20140322148A1 (en) * 2011-11-25 2014-10-30 Adrianna Janell Jackson Oil Compositions and Methods for Increasing Hair Growth and/or Preventing Hair Loss
JP2015526484A (ja) * 2012-08-31 2015-09-10 バイオラブ・サヌス・ファーマセウティカ・エルティーディーエー． フィナステリドおよびミノキシジルポリマーナノ粒子、その調製方法、それを含有する水性懸濁液、医薬組成物、ならびにその使用
KR20170059961A (ko) * 2012-01-25 2017-05-31 한미약품 주식회사 두타스테라이드 함유 자가 유화 약물전달 시스템용 조성물 및 이의 제조 방법

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4299826A (en) * 1979-10-12 1981-11-10 The Procter & Gamble Company Anti-acne composition
JPS5682843A (en) * 1979-12-08 1981-07-06 Nippon Oil Co Ltd Wax emulsion
US4950475A (en) * 1988-07-19 1990-08-21 Imaginative Research Associates, Inc. Novel film-forming gels with high concentrations of humectants and emollients
US5030374A (en) * 1989-07-17 1991-07-09 International Research And Development Corporation Clear neutral non-foaming rapidly-rinsable gel facial cleanser formulation
US5422361A (en) * 1989-12-20 1995-06-06 Schering Corporation Stable cream and lotion bases for lipophilic drug compositions
ZA954599B (en) * 1994-06-07 1996-01-26 Allergan Inc Stable gel formulation for topical treatment of skin conditions
US7074747B1 (en) 1999-07-01 2006-07-11 Johnson & Johnson Consumer Companies, Inc. Cleansing compositions
US20020035070A1 (en) 2000-07-26 2002-03-21 The Procter & Gamble Company Method of regulating hair growth using metal complexes of oxidized carbohydrates
US20070292355A1 (en) 2002-10-25 2007-12-20 Foamix Ltd. Anti-infection augmentation foamable compositions and kit and uses thereof
US7854940B2 (en) * 2004-09-16 2010-12-21 Arch Chemicals, Inc. Broad spectrum preservation blends
WO2007046097A2 (en) 2005-10-21 2007-04-26 Medidermis Ltd. Topical compositions for the treatment of depilation-induced skin irritation or prevention thereof
US8367112B2 (en) 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
WO2009072007A2 (en) 2007-12-07 2009-06-11 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
WO2012135337A2 (en) 2011-03-28 2012-10-04 Mary Kay Inc. Topical skin care formulations comprising plant extracts
US10441567B2 (en) 2014-01-17 2019-10-15 Ligand Pharmaceuticals Incorporated Methods and compositions for modulating hormone levels
US11260013B2 (en) 2016-07-15 2022-03-01 Medicell Technologies, Llc Compositions and methods for providing hair growth
ES2985673T3 (es) 2017-07-11 2024-11-06 Shilpa Medicare Ltd Composiciones tópicas de dutasterida
US11311529B2 (en) * 2018-11-08 2022-04-26 Varsona Therapeutics, Inc. Topical formulations of 5-α-reductase inhibitors and uses thereof
US11311556B2 (en) 2020-05-13 2022-04-26 Varsona Therapeutics, Inc. Topical dutasteride emulsions for treating endocrine therapy-induced alopecia

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030191035A1 (en) * 2002-03-26 2003-10-09 Alberto-Culver Company Hair conditioning composition
US20090069364A1 (en) * 2003-10-10 2009-03-12 Carrara Dario Norberto R Pharmaceutical compositions of 5-alpha-reductase inhibitors and methods of use thereof
US20060204588A1 (en) * 2005-03-10 2006-09-14 Elan Pharma International Limited Formulations of a nanoparticulate finasteride, dutasteride or tamsulosin hydrochloride, and mixtures thereof
US20100048598A1 (en) * 2008-08-21 2010-02-25 Sateesh Kandavilli Topical compositions comprising 5-alpha reductase inhibitors
JP2012504135A (ja) * 2008-09-27 2012-02-16 ジャイナ ファーマシューティカルズ，インコーポレーテッド 経口適用および局所適用のための脂質系薬学的調製物、ならびにそれらの組成物、方法、および使用
JP2013543004A (ja) * 2010-11-18 2013-11-28 ホワイト マウンテン ファーマ，インコーポレイテッド 対象における慢性または解決不能な疼痛を処置するための、および／または痛覚閾値を高めるための方法、およびこれに用いる医薬組成物
JP2014500275A (ja) * 2010-12-06 2014-01-09 フォリカ，インコーポレイテッド 禿頭症を治療するため、および毛髪の成長を促進するための方法
US20140322148A1 (en) * 2011-11-25 2014-10-30 Adrianna Janell Jackson Oil Compositions and Methods for Increasing Hair Growth and/or Preventing Hair Loss
KR20170059961A (ko) * 2012-01-25 2017-05-31 한미약품 주식회사 두타스테라이드 함유 자가 유화 약물전달 시스템용 조성물 및 이의 제조 방법
JP2015526484A (ja) * 2012-08-31 2015-09-10 バイオラブ・サヌス・ファーマセウティカ・エルティーディーエー． フィナステリドおよびミノキシジルポリマーナノ粒子、その調製方法、それを含有する水性懸濁液、医薬組成物、ならびにその使用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, vol. 117, JPN6023044400, 2017, pages 372 - 384, ISSN: 0005186347 *
JAMADERMATOLOGY, vol. 154, no. 6, JPN6023044401, 11 April 2018 (2018-04-11), pages 670 - 675, ISSN: 0005186346 *
JOURNAL OF COSMETIC AND LASER THERAPY, vol. 14, JPN6023044402, 2012, pages 193 - 199, ISSN: 0005186345 *

Also Published As

Publication number Publication date
US11311529B2 (en) 2022-04-26
US20200147071A1 (en) 2020-05-14
EP3876935A1 (en) 2021-09-15
EP3876935A4 (en) 2022-08-17
WO2020097284A1 (en) 2020-05-14
JP2025032123A (ja) 2025-03-11
US20230021330A1 (en) 2023-01-26

Similar Documents

Publication Publication Date Title
US20230021330A1 (en) Topical formulations of 5-alpha-reductase inhibitors and uses thereof
US11213531B2 (en) High concentration formulation
CN110869020B (zh) 度他雄胺的局部用组合物
US12053481B2 (en) Compositions and methods for deep dermal drug delivery
EA037380B1 (ru) Композиция для местного применения, содержащая кортикостероид
WO2025133909A1 (en) Topical composition comprising dutasteride and minoxidil for alopecia
EP4237080A1 (en) Methods for treating vitiligo lesions having improved efficacy
EP1404336A1 (en) Compositions comprising cgmppde5 inhibitor for transdermal delivery to the erectile tissue of the penis

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20220929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221107

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231031

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240430

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240716

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241114

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20241122

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20241206